BB Biotech AG Included in SIX Swiss Exchange SPI ESG Index

BB Biotech AG has been included in the SPI ESG Index of the SIX Swiss Exchange effective September 22, 2025. This development recognizes the investment company's sustained dedication to responsible investing practices and sustainable corporate governance frameworks. The inclusion serves as external validation of BB Biotech's strategic orientation toward companies that balance financial performance with positive societal impact.

Dr. Christian Koch, Head of BB Biotech at Bellevue Asset Management, emphasized the significance of this milestone, stating that the inclusion confirms the company's commitment to sustainability while reinforcing its strategic focus on biotechnology firms that generate financial value alongside meaningful societal contributions. The SPI ESG Index, launched in 2021, comprises companies from the Swiss Performance Index selected by independent sustainability agency Inrate using rigorous criteria, providing investors with a transparent benchmark for sustainable equity investments in Switzerland. More information about the index methodology can be found at https://www.six-group.com.

The inclusion enhances BB Biotech's visibility within the growing community of ESG-oriented investors and underscores the long-term attractiveness of its investment portfolio. This development comes at a time when sustainable investing continues to gain prominence globally, with investors increasingly seeking companies that demonstrate strong environmental, social, and governance practices. BB Biotech's portfolio consists primarily of innovative drug developers headquartered in the United States and Western Europe, positioning the company as one of the world's largest investors in the biotechnology sector.

The selection process for the SPI ESG Index involves comprehensive evaluation by Inrate, an independent sustainability rating agency that assesses companies based on multiple ESG criteria. This rigorous selection process ensures that only companies meeting high sustainability standards are included in the index. BB Biotech's inclusion reflects its consistent adherence to these standards and its commitment to maintaining robust governance structures. Additional details about sustainability ratings can be accessed through https://www.inrate.com.

This development is particularly significant for the biotechnology investment landscape, as it demonstrates that companies in this sector can successfully integrate sustainability considerations into their investment strategies while pursuing innovative medical breakthroughs. The inclusion may potentially influence other investment companies in the biotechnology space to strengthen their own ESG practices, contributing to broader industry transformation toward more sustainable investment approaches.